In this April 9, 2020 file photo, a chemist displays hydroxychloroquine tablets in New Delhi, India. U.S. regulators are revoking emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19. The Food and Drug Administration said Monday, June 15 that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. (AP Photo/Manish Swarup, File)
By Matthew Perrone
The U.S. Food and Drug Administration is revoking its emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.
The agency said Monday that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.
The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure, and muscle or nerve damage.
The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.
On Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except in formal studies.
Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took the drug preemptively against infection.
Fast Company's Christopher Zara breaks down the OpenAI-Apple legal battle, the AI chip race, and what's next for the future of artificial intelligence.
Glacier CEO Rebecca Hu-Thrams explains how AI-powered robots are making recycling smarter, reducing landfill waste, and transforming the future of waste.
Deep Fission CEO Liz Muller discusses underground nuclear reactors, powering AI, cutting energy costs, and why the future of clean power may be below ground.
Adidas shares how FIFA World Cup 2026 will drive innovation, fan engagement, and billions in opportunity with new gear, technology, and business strategy.
Kristian Kerr, Head of Macro Strategy at LPL Financial, breaks down the firm's 2026 Mid-Year Outlook, recession risks, AI, the Fed, and what's next for markets.
Jess Inskip, Director of Investor Research at StockBrokers.com, breaks down Q2, the AI trade, Fed policy, earnings, and where investors should look next.
